Schedule 13G ownership disclosure
ACRIVON THERAPEUTICS INC
Common Stock, par value $0.001 per share · CUSIP: 004890109
Event date: 2025-04-29
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Perceptive Advisors LLC
Shares: 3,104,139 · Class: 9.9%
- Joseph Edelman
Shares: 3,104,139 · Class: 9.9%
- Perceptive Life Sciences Master Fund, Ltd.
Shares: 3,104,139 · Class: 9.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000950170-25-062201
- Form type
- SCHEDULE 13G/A
- Filer
- Acrivon Therapeutics, Inc.
- CIK
- CIK 1781174
- Filed
- May 01, 2025
- Reporting period
- Apr 29, 2025
- Description
- Schedule 13G beneficial ownership